RY 133.62 0.2325% TD 80.66 0.3608% SHOP 96.69 -2.3432% CNR 170.96 1.5503% ENB 49.46 1.228% CP 112.45 0.196% BMO 126.9 -0.2672% TRI 208.55 -0.2583% CNQ 106.0 0.5406% BN 54.95 -1.0267% ATD 77.31 -0.3609% CSU 3649.3 -1.2892% BNS 63.12 -1.5596% CM 64.92 -0.3683% SU 54.025 0.4369% TRP 49.43 0.5288% NGT 59.66 12.8428% WCN 226.31 -0.593% MFC 31.94 -0.6532% BCE 44.92 -0.817%
The Offer
Company Overview
SUBL is a limited liability exempted company incorporated in the Cayman Islands, with its primary business operations conducted through subsidiaries in Switzerland, Hong Kong SAR, the People’s Republic of China, and Australia. Each subsidiary operates independently with distinct yet complementary activities. As a pioneering biotechnology company, SUBL's focus lies in developing oral, specifically sublingual, delivery methods for peptides and proteins. The listing company, BioLingus (Cayman) Limited, functions as a holding company without material operations and was established on August 8, 2018. Serving as its parent entity, BioLingus (Cayman) Limited oversees BioLingus (BVI) Limited, also a holding company without material operations, incorporated in the British Virgin Islands on August 2, 2019. The Swiss wholly owned subsidiary, Biolingus IP GmbH, founded on July 25, 2014, by founders Yves Decadt, Thomas Ko, and Didier Coquoz, focuses on researching improved efficacy in sublingual/transmucosal delivery for metabolic diseases like diabetes and obesity. Following years of research, SUBL has identified two primary areas of application for its technology: Metabolics (primarily obesity and diabetes) and Immunology (mainly allergy and auto-immune disorders).
Xxxxxx Xxxxxx Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx
Xxxxxx Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Xxxxxx
Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .
Enter your details below and our team will help you to decide if this product is best for you.
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
CA 
AU
UK
US
NZ
Please wait processing your request...